Ginkgo Bioworks Holdings, Inc. logo

Ginkgo Bioworks Holdings, Inc. (DNA)

Market Closed
10 Aug, 20:00
XMEX XMEX
MX$
170. 00
0
0%
MX$
- Market Cap
- P/E Ratio
- Div Yield
20 Volume
-0.32 Eps
MX$ 170
Previous Close
Add Transaction
Day Range
170 170
Year Range
150 289
Want to track DNA and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

DNA closed yesterday higher at MX$170, an increase of 0% from Friday's close, completing a monthly increase of 13.3333% or MX$20. Over the past 12 months, DNA stock lost -41.1765%.
DNA is not paying dividends to its shareholders.
The last earnings report, released on May 05, 2026, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0.5262%, based on the last three reports.
Ginkgo Bioworks Holdings, Inc. has completed 1 stock splits, with the recent split occurring on Aug 20, 2024.
The company's stock is traded on 2 different exchanges and in various currencies, with the primary listing on NYSE (USD).

DNA Chart

Ginkgo Bioworks Q2 Earnings Call Highlights

Ginkgo Bioworks Q2 Earnings Call Highlights

Ginkgo Bioworks NYSE: DNA reported second-quarter 2026 revenue of $20 million, down 48% from the year-earlier period, as the company continued to shift its focus toward autonomous laboratory systems, contract research services and related software.

Marketbeat | 4 days ago
Ginkgo Bioworks Holdings, Inc. (DNA) Q2 2026 Earnings Call Transcript

Ginkgo Bioworks Holdings, Inc. (DNA) Q2 2026 Earnings Call Transcript

Ginkgo Bioworks Holdings, Inc. (DNA) Q2 2026 Earnings Call Transcript

Seekingalpha | 5 days ago
Core DNA: Coreweave and Nebius Couldn't Be More Different and Why It Matters

Core DNA: Coreweave and Nebius Couldn't Be More Different and Why It Matters

CoreWeave (NASDAQ: CRWV) and Nebius Group (NASDAQ: NBIS | NBIS Price Prediction) just delivered Q1 2026 results that look similar on the surface: both are NVIDIA-backed AI cloud providers chasing hyperscaler contracts.

247wallst | 1 week ago

Ginkgo Bioworks Holdings, Inc. (DNA) FAQ

What is the stock price today?

The current price is MX$170.00.

On which exchange is it traded?

Ginkgo Bioworks Holdings, Inc. is listed on XMEX.

What is its stock symbol?

The ticker symbol is DNA.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, no market cap data is available.

Has Ginkgo Bioworks Holdings, Inc. ever had a stock split?

Ginkgo Bioworks Holdings, Inc. had 1 splits and the recent split was on Aug 20, 2024.

Ginkgo Bioworks Holdings, Inc. Profile

Biotechnology Industry
Healthcare Sector
Jason Kelly CEO
XMEX Exchange
US37611X2099 ISIN
US Country
485 Employees
- Last Dividend
20 Aug 2024 Last Split
19 Apr 2021 IPO Date

Overview

Ginkgo Bioworks Holdings, Inc., operational since 2008 and based in Boston, Massachusetts, specializes in the advanced sector of cell programming within the United States. This revolutionary company has built a platform that leverages the capabilities of biology for the development and production of products that span across various industries. By harnessing the power of cell programming, Ginkgo Bioworks aims to transition the production of a vast range of products towards more sustainable and biologically driven processes. The company's efforts are pivotal in paving the way for innovations in multiple sectors, including pharmaceuticals, agriculture, industrial chemicals, food, and nutrition, showcasing the versatility and potential of biotechnology.

Products and Services

  • Novel Therapeutics

    Ginkgo Bioworks employs its cell programming platform to advance the field of medicine by developing novel therapeutics. This includes drugs and treatments that are based on the manipulation of biological systems, aiming to offer more effective and personalized healthcare solutions.

  • Food Ingredients

    By programming cells to produce specific compounds, Ginkgo Bioworks is able to create innovative food ingredients. This can lead to healthier, more sustainable, and potentially cheaper alternatives to traditional ingredients, marking a significant advance in the food and nutrition industry.

  • Chemicals Derived from Petroleum

    The company also focuses on the biosynthesis of chemicals that are traditionally derived from petroleum, offering a more sustainable pathway to produce these essential compounds. This approach not only helps in reducing the environmental impact but also in creating materials with potentially enhanced properties.

  • Pharma and Biotech Applications

    Ginkgo Bioworks serves the pharmaceutical and biotechnology sectors by providing solutions that speed up drug discovery processes, improve the efficacy of existing therapies, and contribute to the development of new treatment modalities.

  • Agriculture

    In agriculture, the company's technologies are used to enhance crop yield, optimize the nutritional value of food products, and create more resilient agricultural systems against climate change and pests.

  • Industrial and Environmental Solutions

    Ginkgo Bioworks is also at the forefront of developing biotechnological solutions for environmental and industrial challenges, including pollution control, waste reduction, and the creation of renewable energy sources.

  • Consumer and Technology Products

    The company influences the consumer goods and technology sector by integrating biologically engineered solutions into everyday products, thereby improving quality, sustainability, and functionality.

  • Government and Defense

    Lastly, Ginkgo Bioworks collaborates with government and defense industries to develop biosecurity and health monitoring systems, showcasing the critical role of biotechnology in national security and public health.

Contact Information

Address: 27 Drydock Avenue
Phone: 877 422 5362